CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Trial Details

NCT ID

NCT06346912

Phase

EARLY_PHASE1

Sponsor

Zhejiang University

Status

RECRUITING

Cancer Type

Non-Hodgkin Lymphoma Lymphoma

Interventions

• CD19-BAFF Targeted CAR T-cells

Locations (sample)

• Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

• 1\. Gender unlimited，18\< Age;
• 2\. Patients diagnosed with B-cell acute lymphoblastic leukemia through histological or immunophenotyping tests; The clear diagnosis of B-cell non …
• 3\. Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions):
• CR not achieved after standardized chemotherapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.